EPISODE · Nov 25, 2015 · 8 MIN
UPDATE: What happened at the FDA panel review of one Duchenne drug?
from Signal · host Stat
An FDA panel reviewed a drug for Duchenne muscular dystrophy called drisaperson on Tuesday. What it found is not encouraging. The Signal podcast takes a look at what happened and where things go from here.
NOW PLAYING
UPDATE: What happened at the FDA panel review of one Duchenne drug?
No transcript for this episode yet
Similar Episodes
May 14, 2026 ·3m
May 14, 2026 ·28m
May 14, 2026 ·75m
May 14, 2026 ·18m